Cooperation of Mast Cells and Basophils in Allergy

Enrico Crivellato1 and Domenico Ribatti**

1Department of Experimental and Clinical Medicine, Anatomy Section, University of Udine Medical School, Italy
2Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Italy

Abstract

Mast cells and basophils are granulated cells, which share similar phenotypic and functional properties. They express complementary and partially overlapping roles in acquired and innate immunity, including both effector and regulatory activities, but they also display important distinctive features as to developmental lineage, mediator content, and function. They cooperate in expanding and/or modulating inflammation as well as in mediating subsequent tissue repair. Mast cells release in the inflammatory scenario a series of potent proangiogenic molecules that stimulate vessel sprouting and new vessel formation. Recent data suggest that basophils may also play a role in inflammation-related angiogenesis, principally but not exclusively through the expression of several forms of VEGF and their receptors. This review focuses on the potential cooperative link between mast cells and basophils in promoting angiogenesis during allergic inflammation. We discuss the multifaceted roles of mast cells and basophils in the inflammatory setting during allergic diseases and whether these cells can be both source and target cells for proangiogenic mediators.

Keywords: Mast cells; Basophils; Allergic inflammation; Angiogenesis

Introduction

Mast cells and basophils represent distinct haematopoietic lineages that can express complementary or overlapping functions in the context of acute and chronic immunoglobulin E (IgE)-associated allergic responses [1,2]. They both contribute to leukocyte recruitment, stromal and tissue cell activation, modulation of immune reactions, tissue remodelling and angiogenesis. Both cell types play a critical role in innate immunity to parasite and bacterial infection [3] and can be activated by bacterial and viral proteins [4,5]. Both cells express immunoregulatory functions in IgE-dependent inflammatory reactions [6,7]. In addition, both they synthesize and release VEGF, the most potent proangiogenic mediator known so far [7,8]. Remarkably, both cell types have the potential to present antigens to T cells through HLA class I and II molecules. Under certain conditions, indeed, mast cells and basophils can directly activate T cells by functioning as antigen presenting cells [9]. This review will discuss recent advances in understanding the potential cooperative link between mast cells and basophils, which may promote distinct aspects of immune reactions in the course of allergic inflammation.

General Biology of Mast Cells and Basophils

Mast cells and basophils were first described by the German pathologist Paul Ehrlich as granulated metachromatic cells [10,11]. He coined the term "Mastzellen" which means well-fed cells, because the cytoplasm of these cells was stuffed with granular material. The complex development of their discovery and the subsequent elucidation of their properties revealed that these cells share similar phenotypic and functional features but differ in important aspects of natural history, mediator content, and function. The main histochemical difference between mast cells and basophils is their distinct metachromatic staining, which primarily reflects their different content of proteoglycans of cytoplasmic granules. For instance, chondroitin sulfates are present in both mast cells and basophils, whereas heparin is detectable in the cytoplasm of these cells was stuffed with granular material. The

Keywords: Mast cells; Basophils; Allergic inflammation; Angiogenesis

Introduction

Mast cells and basophils represent distinct haematopoietic lineages that can express complementary or overlapping functions in the context of acute and chronic immunoglobulin E (IgE)-associated allergic responses [1,2]. They both contribute to leukocyte recruitment, stromal and tissue cell activation, modulation of immune reactions, tissue remodelling and angiogenesis. Both cell types play a critical role in innate immunity to parasite and bacterial infection [3] and can be activated by bacterial and viral proteins [4,5]. Both cells express immunoregulatory functions in IgE-dependent inflammatory reactions [6,7]. In addition, both they synthesize and release VEGF, the most potent proangiogenic mediator known so far [7,8]. Remarkably, both cell types have the potential to present antigens to T cells through HLA class I and II molecules. Under certain conditions, indeed, mast cells and basophils can directly activate T cells by functioning as antigen presenting cells [9]. This review will discuss recent advances in understanding the potential cooperative link between mast cells and basophils, which may promote distinct aspects of immune reactions in the course of allergic inflammation.

General Biology of Mast Cells and Basophils

Mast cells and basophils were first described by the German pathologist Paul Ehrlich as granulated metachromatic cells [10,11]. He coined the term "Mastzellen" which means well-fed cells, because the cytoplasm of these cells was stuffed with granular material. The complex development of their discovery and the subsequent elucidation of their properties revealed that these cells share similar phenotypic and functional features but differ in important aspects of natural history, mediator content, and function. The main histochemical difference between mast cells and basophils is their distinct metachromatic staining, which primarily reflects their different content of proteoglycans of cytoplasmic granules. For instance, chondroitin sulfates are present in both mast cells and basophils, whereas heparin is detectable in the cytoplasm of these cells was stuffed with granular material. The
mediators stored preformed in mast cell granules are histamine, heparin, serine proteases such as tryptase and chymase, cathepsin G, peroxidase, many acidic hydrolases, carboxypeptidases and antimicrobial peptides such as cathelicidins [17]. Basophil granules contain less amount of histamine, lack heparin but contain proteoglycans like chondroitin sulphates and Charcot-Leyden crystal protein. In some allergic settings, circulating basophils may contain tryptase, chymase, carboxypeptidase A, and express the c-kit receptor—that normally lacks on the basophils surface—which suggests that these cells may modulate their phenotype [18]. Newly generated mediators consist of arachidonic acid metabolites, principally cysteinyl leukotrienes (LTB4 and LTC4), prostaglandins (PGE2 and PGD2), and platelet-activating factor (PAF) and cytokines such as tumor necrosis factor (TNF-α, β), transforming growth factor (TGF)-β, fibroblast growth factor (FGF)-2, vascular endothelial growth factor (VEGF), granulocyte macrophage-colony stimulating factor (GM-CSF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), interferon (IFN)-α, -β, and -γ, and IL-4, IL-5, IL-6, IL-1β and IL-13. By contrast, LTC4 and PAF are the only identified lipid mediators released by basophils [19]. All these mediators can exert profound effects on inflammation, immunity, haematopoiesis, tissue remodelling and other biological functions. Human and mouse mast cells secrete several C-C and CXC chemokines, including monocyte chemotactic protein (MCP)-1 (CCL-2) and macrophage inflammatory protein (MIP)-1α (CCL-3). IL-8 (CXCL-8) has chemokine functions as well. Basophils are a major source of pro-allergic cytokines, such as IL-4, and have been shown to be responsible for 72% of IL-4 protein-positive cells in the bronchial mucosa during allergen-induced asthmatic reactions [20]. These cells also comprise the dominant IL-4-producing cell in the bronchoalveolar lavage fluid following segmental lung challenge [21]. Basophils also secrete VEGF, IL-6 and IL-13 [19].

**Mast Cell and Basophil in Allergy**

Both mast cells and basophils express the tetrameric αβγδ form of the high-affinity receptor FceRI for IgE on their surface and both kinds of cells are crucial effectors in T helper 2 (Th2)-cell-dependent, IgE-associated allergic disorders and immune responses to parasites [22-25]. IgE play a crucial role in the immediate hypersensitivity response but other IgE-independent mechanisms, such as G protein-coupled receptor and Toll-like receptor activation processes may intervene [26,27]. Activated mast cells and basophils release Th2 cytokines (IL-4, IL-5, IL-9 and IL-13) that polarize the immune response, and produce various bioactive chemical mediators, such as histamine and lipid metabolites, that provide vasoactive, chemotactic and immunoregulatory functions [28,29].

In addition to their roles in classic acute IgE-associated immediate hypersensitivity responses, several lines of evidence indicate that mast cells and basophils can also contribute to late-phase and chronic allergic reactions [30-32]. A key molecule in this context is IL-33. IL-33 is a member of the IL-1 cytokine family, which is preferentially and constitutively expressed in epithelial cells, and it is especially localized in the cell nucleus. The nuclear IL-33 is released by necrotic cells after tissue injury and subsequently provokes local inflammation. This activation causes the cells to produce Th2 cytokines, which contribute to the development of allergy. The IL-33 receptor (IL-33R) is a heterodimer comprised of IL-1RL1 and IL-1 receptor accessory protein (IL-1RACP). Genetic polymorphism of IL-33 and IL-1RL1 is suspected of causing susceptibility to development of asthma in certain patients. Genetic polymorphism of IL-1RL1 has also been identified in patients with atopic dermatitis, and expression of IL-33 is increased in inflamed skin from these patients, suggesting involvement of IL-33 in the development of atopic dermatitis. Human peripheral blood or cord blood progenitor cell-derived MCs and mouse peritoneal and bone marrow-derived cultured MCs constitutively express IL-1 RIL1 that induces expression of mouse MC protease-6, prolong survival and promote adhesion of naïve human and murine MCs without inducing degranulation in response to IL-33. IL-33 can enhance IgE/Ag-, monomeric IgE-, C5a-, SCF- and NGF-mediated cytokine production in human and mouse MCs. In human and/or mouse naïve basophils that constitutively express IL-1RL1, IL-33 can induce production of such cytokines and chemokines as IL-4, IL-5, IL-6, IL-8, IL-13, GM-CSF, CCL2, CCL3 and CCL4 and cell adhesion by promoting CD11b expression, without inducing degranulation or migration. IL-33 enhances IgE-mediated degranulation and migration as well as IgE- and IL-3-mediated cytokine and chemokine production in human and mouse basophils. IL-33 also enhances the receptor for leptin on human basophils, suggesting that IL-33 may be involved in metabolic abnormalities associated with inflammation via basophil activation. In ragweed pollen-induced allergic rhinitis, IL-33 enhances release of histamine and chemotactarctant factors for eosinophils and basophils by mast cells and basophils, contributing to local inflammation in the early and late phases of diseases. Another proinflammatory cytokine recently found to be involved in allergy is IL-18. IL-18 plays an important role in Th1/Th1c1 polarization and promoting the production of Th2 cytokines (e.g., IL-4, IL-5, IL-9, and IL-13) by T cells, NK cells, basophils, and mast cells. IL-18 can act as a co-factor for Th2 cell development and IgE production, and also plays an important role in the differentiation of Th17 cells. IL-18 is a key player in the pathogenesis of inflammatory diseases such as atopic dermatitis. Furthermore, many lines of evidence suggest that IL-18 plays a key role in the pathogenesis of pulmonary inflammatory diseases, including bronchial asthma and chronic obstructive pulmonary disease.

In asthmatics, the number of the MCs increases at sites of inflammation. Activation of MCs is detected by higher spontaneous release of histamine by mast cells obtained from the bronchoalveolar lavage (BAL) of asthmatics and by elevated levels of tryptase and PGD2 in BAL. MCs have been shown to change their degranulation pattern from acute to chronic allergic responses [33]. Many clinical symptoms of IgE-dependent late-phase reactions, both in the respiratory tract, gastrointestinal tract and the skin, reflect the actions of the leukocytes recruited to these sites by MCs and basophils through release of TNF-α, IL-6, IL-8, neutral proteases, as well as histamine and lipid mediators [34]. Recent experimental work on mice has demonstrated that there is a sequential engagement of FceRI on MCs and basophil histamine H(4) receptor and FcεRI in allergic rhinitis. Results demonstrate the development of allergic rhinitis proceeded in two distinct stages: histamine release from FceRI-activated mast cells, followed by histamine-mediated recruitment of H(4)R-expressing basophils to the nasal cavity and activation through FcεRI [35]. Certain MC cytokines, such as TNF-α, VEGF, FGF-2 and TGF-β, contribute to chronic allergic inflammation through effects on fibroblasts, vascular endothelial cells, and other cells resident at the sites of these reactions. Persistent chronic allergic inflammation can result in remodelling of the affected tissues and these structural changes are often associated with activation of the angiogenic process.

**Inflammation, Angiogenesis and Tissue Remodelling**

Airway tissues from patients with asthma characterizationally show blood vessel proliferation in the mucosa and submucosa. The major structural and functional changes of the airway microcirculation include the proliferation of new vessels, increased vascular area of the
medium and small airways, increased blood flow and microvascular permeability, and edema formation in the airway wall [36,37]. Inflammation and angiogenesis are driven by numerous factors among which cytokines of the CXC family provide a pivotal role [38]. IL-33 can induce production of chemokines such as CCL2, CCL3 and CCL4 by human and mouse naïve basophils that constitutively express IL-1RL1. Thus, not only CXC chemokines are responsible for leukocyte recruitment to inflamed tissues but they also regulate the inflammatory reaction leading to angiogenesis, tissue repair and new tissue generation [39-42].

MCs and basophils participate in the same inflammatory scenario along with other blood-born and tissue-resident cells in the course of different allergic conditions [43]. These cells cooperate in expanding and/or modulating inflammation as well as in mediating tissue remodelling and angiogenesis [44]. Many mediators and receptors are involved in such paracrine and autocrine networks. MCs and basophils are endowed with a wide set of chemokine receptors. Basophils constitutively express CCR1, CCR2, CCR3, CXCR1, CXCR3, and CXCXR4 [6]. CCR3 is highly expressed on human basophils and can be activated by eotaxin (CCL11), RANTES (CCL5), MCP-3 (CCL7) and MCP-4 (CCL13) [45]. In contrast to human basophils, mouse basophils do not express CCR3. Interestingly, CCR3 is also expressed by about 25% of lung mast cells in subjects with bronchial asthma [46]. Upon IgE overproduction, mouse basophils release CCL22, which is a potent chemotactractant for Th2 cells and has been implicated in Th2-predominant allergic inflammation [47].

MCs and basophils are a major source of several angiogenic factors among which the VEGF, the most potent proangiogenic mediator [8,7]. VEGF may be released by MCs by exocytosis or in the absence of degranulation. Selective release of VEGF by human MCs is mediated by CRH or by activation of the EP(2) receptor by PGE2 [48,49]. VEGF is also produced by human basophils [8], which express the tyrosine kinase VEGF-A receptor VEGFR-2/KDR. VEGF-A also functions as basophil chemotactractant providing a novel autocrine loop for basophil self-recruitment. Both MCs and basophils release histamine, which displays angiogenic activity in several in vitro and in vivo settings [50]. MCs synthesize and release other potent angiogenic cytokines, such as FGF-2, the serine proteases tryptase and chymase, IL-8, TGF-β, TNF-α and NGF. In addition, both MCs and basophils express the high affinity urokinase plasminogen activator receptor (uPAR) for the urokinase plasminogen activator (uPA) [51,52]. uPA is a potent chemotactractant for both kind of cells and, remarkably, uPA and uPAR are involved in tissue remodelling and vessel sprouting. MCs from human uterine leiomyomas contain leptin, a 167-amino-acid residue peptide mainly secreted by adipocytes which, besides its involvement in obesity development, expresses angiogenic activity [53]. In addition, human skin, lung and synovial MCs contain matrix metalloproteinase (MMP)-9, which degrade and remodel the extracellular matrix (ECM) thus releasing ECM-bound angiogenic factors [54].

Concluding Remarks

MCs and basophils are effector cells in allergic conditions such as bronchial asthma. They can also cooperate in the process of tissue remodelling associated with allergic inflammation. These cells produce numerous mediators and express surface receptors that provide the basis for complex paracrine and autocrine cross-talking networks. They are both source and target cells for proinflammatory and proangiogenic mediators. Understanding the increasingly complexity of the interaction between basophils and MCs as well as between these cells and the other tissue resident and inflammatory cells in the allergic scenario would mean increase our capacity to modify and control dangerous aspects of inflammation.

Acknowledgement

The authors do not declare any conflict of interest. This study has been supported by MIUR local funds to the Department of Medical and Morphological Research, Anatomy Section, University of Udine.

References
